D.C. Circuit Rejects Mylan's Bid To Make Generic Duragesic

Law360 (December 7, 2004, 12:00 AM EST) -- A U.S. appeals court in Washington, D.C. has rejected Mylan Laboratories' bid to market a generic version of Johnson & Johnson's Duragesic pain-relief skin patch.

The United States Court of Appeals for the District of Columbia Circuit upheld a June decision by the Food and Drug Administration and affirmed another court ruling that allowed Johnson & Johnson to retain exclusive rights to Duragesic until January as a reward for testing the effects of the drug on children.

The D.C. Circuit held that the FDA did not...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.